Insmed Inc. has announced the successful results of its TPIP Phase 2b study for the treatment of pulmonary arterial hypertension (PAH). The study met its primary endpoint with high statistical significance, and positive results were observed for all secondary efficacy endpoints. As a result, Insmed plans to engage with the U.S. Food and Drug Administration (FDA) to discuss the design of a Phase 3 trial for PAH. The company aims to initiate a Phase 3 trial for pulmonary hypertension associated with interstitial lung disease (PH-ILD) by the end of 2025 and a Phase 3 trial for PAH in early 2026. Insmed will host an investor conference call at 8:00 AM ET on June 10, 2025, to discuss these findings. A replay of the call will be available through June 17, 2025, and the webcast will be archived for 90 days on the company's website.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.